Home/Pipeline/Budesolv

Budesolv

Allergic Rhinitis

Phase 2Active

Key Facts

Indication

Allergic Rhinitis

Phase

Phase 2

Status

Active

Company

Marinomed Biotech

About Marinomed Biotech

Marinomed Biotech is a publicly traded biopharmaceutical company developing therapies in virology and immunology based on its patented Marinosolv® technology platform. Its pipeline includes clinical-stage programs for allergic rhinitis and viral infections, alongside commercial-stage medical devices. The company faces near-term financial pressures, as evidenced by recent capital measures, and is exploring strategic options for its core platform while advancing its key clinical asset, Budesolv.

View full company profile

Therapeutic Areas

Virology Immunology

Other Allergic Rhinitis Drugs

Drug	Company	Phase	Status
RYALTRIS®	glenmark	Marketed	Commercialized; Direct U.S. Launch
Azelastine Hydrochloride	Coral Drugs	Commercial	Active
INI-2004	Inimmune	Phase 2	Active
CEN501	NeuCen Biomedical	Preclinical	Active